The Effects of Streptokinase and Tissue Plasminogen Activator on Left Ventricular Function
One of the major questions remaining in thrombolysis is which drug we should be using. In terms of “head to head” comparisons there are few data. Streptokinase and tissue plasminogen activator have been compared in terms of patency and tissue plasminogen activator has been shown to be superior (1, 2). However, patency cannot be directly extrapolated to patient benefit and direct comparisons of the effects of these drugs on left ventricular function and mortality are required. Left ventricular function can be considered as a surrogate for mortality but in addition the assessment of left ventricular function also evaluates the capacity of a patient to exercise, and relates to quality of life. In this study the effects of streptokinase and tissue plasminogen activator on left ventricular function were compared.
KeywordsLeft Ventricular Function Tissue Plasminogen Activator Intravenous Streptokinase Left Main Disease Intracoronary Streptokinase
Unable to display preview. Download preview PDF.
- 4.R. M. Norris and H. D. White, Therapeutic trials in coronary thrombolysis should measure left ventricular function as the primary end-point of treatment, Lancet,I:1046 (1988).Google Scholar
- 7.F. Van der Werf, and A. E. R. Arnold for the European cooperative study group for recombinant tissue type plasminogen activator (rt-PA), Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction, Br. Med. J., 297:1374–9 (1988).Google Scholar